IX Biopharma on Monday said it has obtained a licence in Australia to bring its product testing in-house, improving speed-to-market and potentially saving on testing costs.

iX Biopharma’s wholly-owned subsidiary iX Syrinx has obtained the good manufacturing practice (GMP) licence issued by the Therapeutic Goods Administration (TGA) of Australia for its testing laboratory in the state of Victoria on September 28. With the new licence, iX Biopharma will now be able to ...

IX Biopharma on Monday said it has obtained a licence in Australia to bring its product testing in-house, improving speed-to market and potentially saving on testing costs.

iX Biopharma has been granted a patent in Israel for its WaferiX drug delivery technology. The patent will expire on October 11, 2033, and will provide key intellectual property protection for the company's WaferiX delivery technology platform in Israel. The company has also received a patent from t...

CATALIST-LISTED iX Biopharma has been granted a patent in Israel for its WaferiX drug delivery technology, it said in a bourse filing on Monday.

CATALIST-LISTED iX Biopharma has received a second notice of allowance from the United States Patent and Trademark Office (USPTO) which enhances intellectual property (IP) protection for the former's lead drug Wafermine.

iX Biopharma has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its patent application on Tuesday (August 4). The patent will provide key intellectual property protection for the Company's WaferiX delivery technology platform, and will provide a further...

SHARES of pharmaceutical company iX Biopharma sank nearly 10 per cent on Wednesday, after it proposed a private placement of about

PHARMACEUTICAL company iX Biopharma has proposed a private placement of about 44.5 million new ordinary shares at 23 Singapore cents apiece to raise a total of S$10.2 million.

PHARMACEUTICAL maker iX Biopharma has commenced the supply of the drugs Wafesil and Silcapvia to patients who have consulted their doctors through telemedicine in Australia, it said in a bourse filing on Tuesday.